Back to News
Market Impact: 0.3
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Source: TechCrunch
Artificial IntelligenceHealthcare & BiotechPrivate Markets & Venture
An AI biotech raised a funding round valuing the company at $2 billion. The company is testing treatments for skin conditions and for preserving weight loss after patients discontinue GLP-1 drugs, highlighting investor backing for AI-enabled drug development and obesity-treatment adjacencies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- Cathie Wood 'always feels better when the market is worried' — here's why
- These funds tout hefty income tied to the tech trade – if you’re willing to deal with the complexity
- Street Calls of The Week
- AI stock selloff drives investors to China, India, and overlooked Asian sectors
- Asia Markets Brace for More AI Volatility